Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EWTX
EDGEWISE THERAPEUTICS, INC.
NASDAQ
$42.76
▼ DOWN 3.24% (-1.43)

KEY STATISTICS

Market Cap$4.60 B
52w High$48.40
52w Low$13.69
Dividend Yield—
Frequency—
P/E-23.11
Volume739.75K
Shares Out.107.59M

COMPANY

LEADERSHIP

Kevin Koch
CHIEF EXECUTIVE
Kevin Koch

COMPENSATION 2026

Salary$670,000
Stock Awards$1,171,625
Incentive Plan Pay$462,300
All Other Comp.$14,000
Total$7,359,546

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 26, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
127

PRICE TARGET

Target High$66.00
Target Low$36.00
Target Median$52.00
Target Consensus$51.90

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$129.17M
NOV
5
THU

PRICE

$42.76 ▼ DOWN 3.24% (−$1.43)
$43.00$43.50$44.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM42.76

About Edgewise Therapeutics, Inc.

https://www.edgewisetx.com ↗

Edgewise Therapeutics, Inc., founded in 2017 in Boulder, Colorado, develops small molecule therapies like EDG-5506 to treat musculoskeletal diseases such as Duchenne and Becker muscular dystrophy.

INDUSTRY

Biotechnology

A PRODUCT EDGEWISE THERAPEUTICS, INC. IS KNOWN FOR

Sevasemten (EDG-5506)
Sevasemten (EDG-5506)

Sevasemten, Edgewise Therapeutics' oral small molecule, is in late-stage trials for Becker and Duchenne Muscular Dystrophy, aiming to prevent contraction-induced muscle damage in rare neuromuscular disorders.

COMPETITORS

COMPETITOR
DYN COMPARE
PTCT COMPARE
RNA COMPARE
SLDB COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
130
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.9M
IWM
0.10% · 1.8M
SCHA
0.07% · 358.3K
DFMC
0.14% · 259.5K
FESM
0.17% · 259.5K
XPH
1.91% · 253.3K
SBIO
2.35% · 132.7K
XRSU.L
0.10% · 64.0K
DWAS
0.49% · 48.1K
RSSL
0.10% · 34.1K
OP
OPTZ
0.39% · 28.2K
BBSC
0.15% · 24.8K
JHSC
0.15% · 24.7K
GSSC
0.04% · 9.9K
MMSC
0.81% · 9.8K
BBC
0.76% · 9.0K
PILL
1.28% · 7.1K
TILT
0.01% · 6.2K
ACSG
0.43% · 5.0K
SGRW
0.71% · 4.7K
ETLZ.DE
0.09% · 4.6K
BIB
0.16% · 3.8K
STXK
0.18% · 3.6K
RFLR
0.12% · 2.6K
BKSE
0.12% · 2.5K
USFMDN.MX
0.01% · 248

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.49%
HOLDERS
280
TOP 12 OF 280 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
15.5M sh · $630.52M
Ra Capital Management, L.P.
10.4M sh · $328.5M
Paradigm Biocapital Advisors LP
10.2M sh · $415.05M
Baker Bros. Advisors LP
7.3M sh · $118.5M
Blackrock, Inc.
6.6M sh · $164.54M
Blackrock Inc.
6.0M sh · $108.34M
Janus Henderson Group Plc
5.9M sh · $186.29M
Fmr LLC
5.5M sh · $223.02M
Novo Holdings A/S
5.3M sh · $217.37M
Braidwell LP
5.2M sh · $84.52M
Vanguard Group Inc
4.9M sh · $120.89M
Driehaus Capital Management LLC
4.7M sh · $192.12M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: GENERAL COUNSEL
MOORE JOHN R
Purchase · 65.0K shares
2026-08-12
★
DIRECTOR, OFFICER: CHIEF SCIENTIFIC OFFICER
Russell Alan J
Purchase · 65.0K shares
2026-08-12
★
OFFICER: CMO
Donovan Joanne M.
Purchase · 65.0K shares
2026-08-12
★
OFFICER: CHIEF FINANCIAL OFFICER
Nofi Michael
Purchase · 48.8K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
BUY 2
OVERWEIGHT 1
NEUTRAL 1
7 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Goldman Sachs NEUTRAL Evercore ISI Group OUTPERFORM Guggenheim BUY RBC Capital OUTPERFORM HC Wainwright & Co. BUY Wedbush OUTPERFORM

SECTORS PEERS

PEERPRICE
QURE$48.72COMPARE
GPCR$47.37COMPARE
VRDN$23.08COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
NUVB$6.66COMPARE
OCUL$10.36COMPARE
MESO$17.44COMPARE